Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients with t(8;21) AML with KIT mutations

Patient no.	Age, y	Sex	WBC count, × 10⁹ cells/L	Additional chromosome abnormalities	Time of relapse, mo	Status of allo-SCT	Survival, mo	KIT mutation
1	8	F	14.10	None	12	Second CR	37	A814S
2	8	M	27.60	–Y	14	Second CR	47^*	N822K
3	8	F	10.77	–X	10	Second CR	25	D816H
4	6	M	34.50	–Y, +4	12	Second CR	26^*	N822K
5	3	F	20.50	None	11	—	25	N822K
6	1	F	4.60	–X, t(7;9)	—	—	32^*	N822T
7	15	M	20.80	–Y	—	First CR	56^*	D816V
8	13	M	66.20	None	—	First CR	30^*	V825A

Patient no.	Age, y	Sex	WBC count, × 10⁹ cells/L	Additional chromosome abnormalities	Time of relapse, mo	Status of allo-SCT	Survival, mo	KIT mutation
1	8	F	14.10	None	12	Second CR	37	A814S
2	8	M	27.60	–Y	14	Second CR	47^*	N822K
3	8	F	10.77	–X	10	Second CR	25	D816H
4	6	M	34.50	–Y, +4	12	Second CR	26^*	N822K
5	3	F	20.50	None	11	—	25	N822K
6	1	F	4.60	–X, t(7;9)	—	—	32^*	N822T
7	15	M	20.80	–Y	—	First CR	56^*	D816V
8	13	M	66.20	None	—	First CR	30^*	V825A

— indicates not applicable.

Patient still alive